Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MOPEVAC-Las vaccine
- Development stage
- Unknown
- Lead developer
- Institut Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
MOPEVAC-Las is a live-attenuated recombinant vaccine candidate developed by the Institut Pasteur for the prevention of Lassa fever. The vaccine is built on the proprietary MOPEVAC (Mopeia vaccine) platform, which utilizes a genetically engineered, hyperattenuated Mopeia virus (MOPV) backbone. MOPV is naturally non-pathogenic to humans, and the MOPEVAC platform is further hyperattenuated by introducing six mutations in the exoribonuclease (ExoN) domain of the nucleoprotein (NP) to prevent the virus from suppressing the host's type I interferon response. To target Lassa virus (LASV), the glycoprotein complex (GPC) gene of MOPV is replaced with the GPC gene of LASV (specifically from the Josiah strain). MOPEVAC-Las is designed to elicit both robust humoral (neutralizing antibodies) and cell-mediated (CD4+ and CD8+ T-cell) immune responses. It is currently being evaluated in a Phase 1 clinical trial (FIRST-IN-MOP) in healthy volunteers.
- Other names
- MOPEVAC-LASMOPEVACLAS
02
Targets
GPC (Lassa virus glycoprotein complex)
Beyond the preview
Go deeper on MOPEVAC-Las vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MOPEVAC-Las vaccine.